<DOC>
	<DOCNO>NCT00086879</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes necessary growth . Drugs use chemotherapy , temozolomide carmustine , work different way stop tumor cell divide stop grow die . It yet know whether erlotinib effective temozolomide carmustine treat recurrent glioblastoma multiforme . PURPOSE : This randomized phase II trial study erlotinib see well work compare temozolomide carmustine treat patient recurrent glioblastoma multiforme .</brief_summary>
	<brief_title>Erlotinib Compared With Temozolomide Carmustine Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare therapeutic activity erlotinib v temozolomide carmustine patient recurrent glioblastoma multiforme . - Compare 6-month progression-free survival patient treat drug . Secondary - Compare safety drug patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral erlotinib* daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . NOTE : *Patients treat enzyme induce anti-epileptic drug ( EIAEDs ) receive high dose erlotinib patient receive anti-epileptic drug EIAEDs . - Arm II : Patients receive prior temozolomide assign receive temozolomide . Patients receive prior temozolomide assign receive carmustine . Patients receive 1 follow treatment regimen : - Patients receive oral temozolomide* daily day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Patients receive carmustine IV daily day 1-3 . Treatment repeat every 56 day 5 course absence disease progression unacceptable toxicity . NOTE : *Chemotherapy-naïve patient receive high dose temozolomide patient receive prior adjuvant chemotherapy . Patients follow every 8 week disease progression every 3 month thereafter . PROJECTED ACCRUAL : A total 100-110 patient ( 50-55 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm glioblastoma multiforme Some oligodendroglial element allow provide make &lt; 25 % tumor Recurrent disease document MRI prior radiotherapy At least 1 bidimensionally measurable target lesion ≥ 2 cm MRI Undergone prior surgery recurrent primary brain tumor 3 month study entry Must clearly limit target lesion ≥ 2 cm OR evidence progressive measurable target lesion OR second measurable target lesion outside surgical area PATIENT CHARACTERISTICS : Age Over 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm ^3 Hepatic AST ALT &lt; 2.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Renal Creatinine &lt; 1.5 time ULN Cardiovascular Clinically normal cardiac function No ischemic heart disease within past 12 month No New York Heart Association grade III IV cardiac insufficiency No unstable angina No arryhthmia Pulmonary DLCO &gt; 70 % predict ( patient randomize receive erlotinib [ arm I ] carmustine [ arm II ] ) No history pulmonary disease would affect pulmonary function include follow : Chronic bronchopneumopathy Pleural effusion Interstitial pnuemonia Pulmonary lymphangitis Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No malignancy except cone biopsied carcinoma cervix adequately treat basal cell squamous cell skin cancer No psychological , familial , sociological , geographical factor would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No prior HERtargeted agent No concurrent growth factor neutrophil count elevation No concurrent epoetin alfa Chemotherapy Prior adjuvant temozolomide allow At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) No 1 prior adjuvant chemotherapy regimen No prior chemotherapy recurrent disease Endocrine therapy Must stable decrease dose corticosteroid least 2 week study entry Radiotherapy See Disease Characteristics More 3 month since prior radiotherapy brain No prior highdose radiotherapy ( &gt; 65 Gy ) , stereotactic radiosurgery , internal radiotherapy unless disease recurrence confirm Surgery See Disease Characteristics Other No prior participation experimental therapies No concurrent CYP3A4 inhibitor ( e.g. , ketoconazole , erythromycin , troleandomycin , cimetidine , grapefruit juice ) No concurrent warfarin coumarin derivative Concurrent lowmolecular weight heparin allow No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>